COVID-19

This section contains information on the COVID-19 antiviral treatment Paxlovid™ (PF-07321332 + ritonavir).

The documents below include correspondence from the HSE-MMP providing an update on Paxlovid™ (PF-07321332 + ritonavir) and highlighting prescribing issues (particularly drug-drug interactions) associated with this medicine.

Due to the risk of drug-drug interactions a full review of patient medication history and interaction risk should be undertaken prior to prescribing Paxlovid™ (PF-07321332 + ritonavir). Refer to the Summary of Product Characteristics and other suitable reference sources (see correspondence below) to review possible medicines that may interact with Paxlovid™ (PF-07321332 + ritonavir).

If a GP wishes to avail of assistance specifically relating to the potential for drug-drug interactions associated with Paxlovid™ (PF-07321332 + ritonavir), the National Medicines Information Centre (NMIC) is available, through their enquiry answering service. This service can be accessed via a secure email (e.g. Healthmail) at nmic@stjames.ie using the template provided below.

For further information on COVID-19 treatments, including Paxlovid™ (PF-07321332 + ritonavir), please consult the HSE Interim Guidance for the Pharmacological Management of Patients with COVID-19 v5.

The HSE-MMP sent correspondence to general practitioners in relation to Paxlovid™ (PF-07321332+ritonavir) in July 2022

The HSE-MMP sent correspondence to general practitioners in relation to Paxlovid™ (PF-07321332+ritonavir) and the support service available from the NMIC in September 2022